Compare NIO Inc. (NIO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs BIO-TECHNE Corp — how do they compare? NIO Inc. trades at $4.62 (market cap $12.12B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: NIO Inc. and BIO-TECHNE Corp are close in size by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while NIO Inc. pays none. Which is the better fit depends on your goals.
| NIO | TECH | |
|---|---|---|
Market Cap | $12.12B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $7.89 | $72.29 |
52-Week Low | $4.44 | $43.31 |
Enterprise Value | $11.35B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $4.74, up 3.04% today but remains under pressure with a bearish technical signal. The company shows strong revenue growth to $87.49 billion in 2025, but profitability remains elusive with a net loss of $15.57 billion. Analyst sentiment is mixed with a 54% buy rating, while recent news highlights delivery growth amid a challenging EV market.
NIO's outlook hinges on achieving profitability amid fierce competition. The stock offers potential for recovery if cost controls improve and deliveries accelerate, but risks include persistent losses, high debt, and macroeconomic pressures in China. Investor patience is required given the long path to sustained earnings.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
